PAMS
DFTX

Pictet Asset Management (Switzerland)’s Definium Therapeutics DFTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,831
Closed -$30K – 1650
2022
Q1 		$30K Hold
1,831
– – ﹤0.01% 1671
2021
Q4 		$38K Hold
1,831
– – ﹤0.01% 1707
2021
Q3 		$64K Buy
+1,831
New +$79.2K ﹤0.01% 1720

Other funds holding DFTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s DFTX Position: Q2 2022 in Review

Pictet Asset Management (Switzerland) sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 1,831 shares — an estimated $30K sold.

Pictet Asset Management (Switzerland) first reported a position in DFTX in Q3 2021 and held it in 3 quarters. The position peaked at $64K in Q3 2021. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Pictet Asset Management (Switzerland) reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Pictet Asset Management (Switzerland) sold 1,831 Definium Therapeutics shares in Q2 2022, an estimated $30K.
  • Pictet Asset Management (Switzerland) first reported a position in Definium Therapeutics in Q3 2021 and held it in 3 quarters.
  • Pictet Asset Management (Switzerland)'s Definium Therapeutics position peaked at $64K in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2022, filed 9 Aug 2022.